The Adequacy of FDA to Assure the Safety of the Nation's Drug Supply: Hearing Before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, First Session, February 13, March 22, 2007, Volume 4 |
From inside the book
Results 1-5 of 37
Page
... Grassley , Hon . Chuck , a Senator from the State of Iowa Prepared statement Submitted material Letter of August 24 , 2005 to Dr. Lester Crawford 129 28882 58 14 90 94 94 96 100 120 122 56 85 Memorandum of Understanding Letter of ...
... Grassley , Hon . Chuck , a Senator from the State of Iowa Prepared statement Submitted material Letter of August 24 , 2005 to Dr. Lester Crawford 129 28882 58 14 90 94 94 96 100 120 122 56 85 Memorandum of Understanding Letter of ...
Page 2
... Senator Charles Grassley , has been a cham- pion in questioning , challenging and over - seeing the FDA's drug approval and post - marketing surveillance . As chairman of the Sen- ate Finance Committee , Senator Grassley has fought , on ...
... Senator Charles Grassley , has been a cham- pion in questioning , challenging and over - seeing the FDA's drug approval and post - marketing surveillance . As chairman of the Sen- ate Finance Committee , Senator Grassley has fought , on ...
Page 3
... Sen- ator Chuck Grassley , the Government Accountability Office stated that problems have been raised about the FDA's management of drug approval and post - market surveillance for the last 30 years . These are certainly complex issues ...
... Sen- ator Chuck Grassley , the Government Accountability Office stated that problems have been raised about the FDA's management of drug approval and post - market surveillance for the last 30 years . These are certainly complex issues ...
Page 4
... Senator Grassley for joining us this morning . He and his staff on the Senate Committee on Finance have spent considerable time investigating the FDA's oversight of drug safety and we look forward to his testimony . Mr. STUPAK . I thank ...
... Senator Grassley for joining us this morning . He and his staff on the Senate Committee on Finance have spent considerable time investigating the FDA's oversight of drug safety and we look forward to his testimony . Mr. STUPAK . I thank ...
Page 8
... Senator Grassley , who is going to be here this morning to testify and for whom we have the greatest respect and extend a very warm welcome , is that this administration appears to be engaged in hiding wrongdoing at FDA . We see this in ...
... Senator Grassley , who is going to be here this morning to testify and for whom we have the greatest respect and extend a very warm welcome , is that this administration appears to be engaged in hiding wrongdoing at FDA . We see this in ...
Other editions - View all
Common terms and phrases
adverse events Advisory Committee meeting agency AIDAC meeting Andrew von Eschenbach antibiotics approved Ketek asked Aventis black box warning BURGESS CDER Chairman Chuck Grassley CISNEROS clinical trials Commissioner concerns conduct Congress criminal investigation data integrity decisions DEGETTE documents Drug Administration drug applications drug approval drug sponsors e-mail effective enrolled ESCHENBACH evaluate FDA employees FDA managers FDA needs FDA officials FDA's February 13 Food and Drug fraud FURBERG going Government Accountability Office GRAHAM hearing infections Kirkman-Campbell label liver failure Medicine monitoring muraglitazar Nissen noninferiority trials Office opening statement patients PDUFA placebo post-marketing postmarket drug safety postmarket safety prescription PSATY public health questions recommendations regulations regulatory response Review Division Ross safety data safety study Sanofi-Aventis scientific Senator GRASSLEY serious staff STUPAK subcommittee submitted telithromycin testimony Thank Vioxx WALDEN whistleblowers WHITFIELD WOOSLEY